Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 3 1Phase 2 1

Status

Completed 3Active not recruiting 1

Sponsor Class

OTHER 4INDUSTRY 1

Study Type

Interventional 3Observational 1

Sponsor

Cancer Type

Gynecologic 4

Conditions

Breast Neoplasms 9481Neoplasms 6589Prostatic Neoplasms 4399Colorectal Neoplasms 3978Lung Neoplasms 3644Carcinoma, Non-Small-Cell Lung 3585Pancreatic Neoplasms 2479Carcinoma, Hepatocellular 2413Leukemia, Myeloid, Acute 2265Multiple Myeloma 2121Stomach Neoplasms 2109Neoplasm Metastasis 1911Head and Neck Neoplasms 1870Ovarian Neoplasms 1773Precursor Cell Lymphoblastic Leukemia-Lymphoma 1734Lymphoma 1730Brain Neoplasms 1702Rectal Neoplasms 1676Melanoma 1656Colonic Neoplasms 1629Leukemia 1500Uterine Cervical Neoplasms 1499Recurrence 1486Esophageal Neoplasms 1312Glioblastoma 1308Lymphoma, Non-Hodgkin 1205Leukemia, Lymphocytic, Chronic, B-Cell 1120Squamous Cell Carcinoma of Head and Neck 1109Urinary Bladder Neoplasms 1078Lymphoma, Follicular 1067

Interventions

liposomal doxorubicin 1Trabectedin 1Hyperthermic Intraperitoneal Chemotherapy 1Docetaxel 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
OTHER × Ovarian Epithelial Cancer Recurrent × Clear all
NCT01376752 2026-05-20

CHIPOR

UNICANCER

Phase 3 Active not recruiting
415 enrolled
Gynecologic

Ovarian Epithelial Cancer Recurrent

NCT02735928 2023-11-15

PARROT

Catholic University of the Sacred Heart

Phase NA Completed
40 enrolled
Gynecologic

Ovarian Epithelial Cancer Recurrent

NCT02394015 2020-03-27

RETRO-ROC

Grupo Español de Investigación en Cáncer de Ovario

Completed
90 enrolled
Gynecologic

Ovarian Epithelial Cancer Recurrent

NCT02026921 2014-01-03

A Phase II Study of Docetaxel and Carboplatin in Late Relapse of Ovarian Cancer

Nordic Society of Gynaecological Oncology - Clinical Trials Unit

Phase 2 Completed
74 enrolled
Gynecologic

Ovarian Epithelial Cancer Recurrent

Data powered by HemOnc (CC BY 4.0) Colophon ⚡